CD40LG and urinary bladder cancer: Following preclinical testing in experimental bladder cancer animal models, a Phase I/IIa clinical trial using adenoviral vector expressing CD40L for immunogene therapy of bladder cancer has been performed and demonstrated a boosted immune activation14.